TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04209777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Blend Chewable Tablet
Description: Lactobacillus-reuteri probiotics were used as an experimental drug.
Study: NCT04531917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The content of the leaflet has a biomedical approach in explaining pain and providing information on the different pain medication classes. This leaflet is mostly available in waiting rooms of oncology centres and units of the Flemish part of Belgium.
Study: NCT00677729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solution contains 1 mg salbutamol plus 3% hypertonic saline
Description: 4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: solution contains 1 mg salbutamol plus 0.9% saline
Description: 4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
Study: NCT01217801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron (ODFS)
Description: Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron (ODT)
Description: Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
Study: NCT02367443

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
Study: NCT00478231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
Study: NCT03135652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
Study: NCT04092400

Intervention type: DEVICE
Intervention: Micro-invasive Glaucoma Surgical Devices
Description: Safety and efficacy of Micro-invasive Glaucoma Surgical Devices
Study: NCT04136418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COPDPredict mobile App
Description: An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients self-manage their COPD using prescribed medication in accordance with basic guidance information
Study: NCT03136354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic assisted Gastrectomy
Study: NCT03566160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryobiopsy probe, administered to study participants
Description: Cryobiopsy probe as a tool for gastrointestinal biopsy
Study: NCT01209611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells
Description: Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
Study: NCT01167517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructional digital video disc (DVD)
Description: Breast milk expression instructions provided by digital video disc at the time of hospital discharge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Instructional digital video disc (DVD)
Description: Breast milk expression instructions provided by digital video disc at the time of hospital discharge
Study: NCT01208428

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cognitive behavioral therapy
Description: Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Religious cognitive behavioral therapy
Description: Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
Study: NCT01597479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
Study: NCT01944787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine
Description: IV Hydration at 125 cc hour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV Hydration at 250cc hour
Description: IV Hydration at 250 cc hour
Study: NCT04977661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E is one of the body's most effective chain-breaking antioxidants that has shown to delay the pathogenesis of NASH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic acid
Description: is a metabolic by-product of intestinal bacteria and has been proven to be useful in the non-surgical treatment of cholesterol gallstones and primary biliary cirrhosis (PBC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: it is a well-tolerated medication that improves blood~viscosity and erythrocyte rheological characteristics in individuals with peripheral vascular disease 20. In addition, PTX is a nonspecific phosphodiesterase inhibitor that increases cyclic adenosine monophosphate (cAMP) levels while decreasing TNF-a gene transcription
Study: NCT03432832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EASE
Description: Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Weekly behavioral sessions with a therapist to work on emotional control
Study: NCT03704207

Intervention type: OTHER
Group type: OTHER
Intervention: nNO testing
Description: Collection of already performed clinical data and nNO testing
Study: NCT04107233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
Study: NCT02405221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-CIN (arm)
Description: TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-CIN (thigh)
Description: TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
Study: NCT04209777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Amoxicillin capsules 500mg and metronidazole tablets 400mg antibiotics were used as an active comparator.
Study: NCT00132821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: 21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bupropion
Description: Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal nicotine patch
Description: 21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
Study: NCT00490763

Intervention type: BEHAVIORAL
Intervention: Survey
Description: 7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
Study: NCT00923819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Description: Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard conservative treatment
Description: Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
Study: NCT00751114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Oral administration. 100 mg film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients continued with metformin as usual oral anti-diabetic treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients continued with metformin as usual oral anti-diabetic treatment.
Study: NCT01790971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Intrathecal Morphine
Description: Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
Study: NCT03143868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modality
Description: The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Modality
Description: The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modality
Description: The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
Study: NCT03498781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-only
Description: Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
Study: NCT00622531

Intervention type: DEVICE
Intervention: BNP assay (Siemens ADVIA Centaur BNP)
Description: Diagnostic test

Intervention type: OTHER
Intervention: hidden BNP value
Description: no intervention
Study: NCT03299049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Tablets
Description: CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Tablets
Description: CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
Study: NCT03498781

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
Study: NCT02626572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 5mg
Description: S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 15mg
Description: S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 50mg
Description: S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Study: NCT03299049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Tablets
Description: RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light.
Study: NCT03690037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: Tranexamic Acid: 100 MG/ML Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: Tranexamic Acid: 100 MG/ML Solution for injection
Study: NCT03299049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Tablets
Description: RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
Study: NCT03690037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Tranexamic Acid: Tranexamic Acid 500mg Tablets
Study: NCT02541916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled weaning of immunosuppression
Description: At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy \& LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
Study: NCT03299049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
Study: NCT04563156

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function Test
Description: Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
Study: NCT02731339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Mouse® measurement
Description: The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Mouse® measurement
Description: The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low back pain intensity measurement
Description: Low back pain intensity of the patients was questioned by Visual Analogue Scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low back pain intensity measurement
Description: Low back pain intensity of the patients was questioned by Visual Analogue Scale

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urogenital symptoms measurement
Description: The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disability caused by low back pain
Description: Disability caused by low back pain was assessed with the Oswestry Disability Index

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disability caused by low back pain
Description: Disability caused by low back pain was assessed with the Oswestry Disability Index
Study: NCT01261234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol or Non-Cilostazol
Description: Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
Study: NCT01193192

Intervention type: OTHER
Intervention: Neevo®
Description: A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid
Study: NCT01261234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol or Non-Cilostazol
Description: Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
Study: NCT01209611

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
Study: NCT03290248

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244 suspension
Description: B244 suspension in 30ml/bottle
Study: NCT01193192

Intervention type: OTHER
Intervention: Prenatal vitamins
Description: for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
Study: NCT00754728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JACTAX DES
Description: Drug Eluting Stent
Study: NCT00786136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: rosuvastatin
Study: NCT03299049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
Study: NCT00786136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosuvastatin
Description: rosuvastatin
Study: NCT03305094

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure cuff inflation
Description: Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure cuff inflation
Description: Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
Study: NCT03714906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
Study: NCT01469806

Intervention type: DEVICE
Intervention: Zimmer Gender Solutions PFJ Knee Prosthesis
Description: Partial knee arthroplasty of the patello-femoral joint